199 related articles for article (PubMed ID: 36455608)
21. Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations.
Wang L
Curr Res Transl Med; 2022 Jan; 70(1):103320. PubMed ID: 34768218
[TBL] [Abstract][Full Text] [Related]
22. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies.
Lin WY; Wang HH; Chen YW; Lin CF; Fan HC; Lee YY
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212810
[TBL] [Abstract][Full Text] [Related]
23. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
Li H; Song W; Li Z; Zhang M
Front Immunol; 2022; 13():992232. PubMed ID: 36353643
[TBL] [Abstract][Full Text] [Related]
24. CAR-T Cell Therapies From the Transfusion Medicine Perspective.
Fesnak A; Lin C; Siegel DL; Maus MV
Transfus Med Rev; 2016 Jul; 30(3):139-45. PubMed ID: 27067907
[TBL] [Abstract][Full Text] [Related]
25. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
26. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
27. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
Gu T; Zhu M; Huang H; Hu Y
J Zhejiang Univ Sci B; 2022 Oct; 23(10):793-811. PubMed ID: 36226535
[TBL] [Abstract][Full Text] [Related]
28. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
29. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
[TBL] [Abstract][Full Text] [Related]
30. CAR-T treatment for hematological malignancies.
Atrash S; Bano K; Harrison B; Abdallah AO
J Investig Med; 2020 Jun; 68(5):956-964. PubMed ID: 32200355
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
32. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
34. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
36. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
37. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
38. Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies.
Buie LW
Am J Manag Care; 2021 Aug; 27(13 Suppl):S243-S252. PubMed ID: 34407360
[TBL] [Abstract][Full Text] [Related]
39. Current status of chimeric antigen receptor therapy for haematological malignancies.
Maude S; Barrett DM
Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
[TBL] [Abstract][Full Text] [Related]
40. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
Elsallab M; Levine BL; Wayne AS; Abou-El-Enein M
Lancet Oncol; 2020 Feb; 21(2):e104-e116. PubMed ID: 32007196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
